RxDoctor Payments DataLook up a doctor →

John Paul Iii McKenzie, MD

Clinical Cardiac Electrophysiology · Glendale, CANPI 1366422685

Payments from drug & device makers

$192,103in general payments, 2019–2025

Across 1,062 payments — averaging $180.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$66K
  • Acutus Medical, Inc.$44K
  • Abbott$43K
  • Medtronic$24K
  • Galvanize Therapeutics, Inc$3K
  • Medical Device Business Services, Inc.$2K
  • plus $10K from 33 others
$10,077in research payments, 2019–2025

Across 5 payments — averaging $2015.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$10K

What the payments were for

  • Consulting fees$50,73245%
  • Speaking & faculty fees$2,1032%
  • Travel & lodging$13,74612%
  • Food & beverage$44,98840%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,103 in reported general payments places this provider in the 80th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$986,225
Medicare patients
2,509
Services billed
11,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban314$230,930
MultaqDronedarone Hcl268$222,665
XareltoRivaroxaban233$166,206
EntrestoSacubitril/Valsartan17$15,229
Dofetilide17$6,364
Propafenone Hcl147$5,565
Flecainide Acetate293$5,111
Mexiletine Hcl40$3,743
SotalolSotalol Hcl197$2,493
Metoprolol Succinate237$1,933
Amiodarone Hcl194$1,705
Diltiazem 24hr Er (Cd)Diltiazem Hcl73$1,448
Carvedilol155$575
ClopidogrelClopidogrel Bisulfate100$573
Metoprolol Tartrate123$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$49$222,665268 claims
Johnson & JohnsonXarelto$172$166,206233 claims
NovartisEntresto$209$15,22917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →